Mosapramine

Mosapramine
Clinical data
Trade names	Cremin (クレミン, JP)
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral (tablets, oral solution)
ATC code	N05AX10 (WHO) ;
Legal status
Legal status	Rx-only (JP);
Identifiers
	IUPAC name 1'-[3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl]spiro[1,5,6,7,8,8a-hexahydroimidazo[1,2-a]pyridine-3,4'-piperidine]-2-one;
CAS Number	89419-40-9 ;
PubChem CID	4257;
DrugBank	DB13676;
ChemSpider	4107;
UNII	04UZQ7O9SJ;
KEGG	D08235 ;
CompTox Dashboard (EPA)	DTXSID0048846 ;
Chemical and physical data
Formula	C28H35ClN4O
Molar mass	479.07 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCN2C(C1)NC(=O)C23CCN(CC3)CCCN4C5=CC=CC=C5CCC6=C4C=C(C=C6)Cl;
	InChI InChI=1S/C28H35ClN4O/c29-23-12-11-22-10-9-21-6-1-2-7-24(21)32(25(22)20-23)16-5-15-31-18-13-28(14-19-31)27(34)30-26-8-3-4-17-33(26)28/h1-2,6-7,11-12,20,26H,3-5,8-10,13-19H2,(H,30,34); Key:PXUIZULXJVRBPC-UHFFFAOYSA-N;
	(verify)

Mosapramine (Cremin) is an atypical antipsychotic used in Japan for the treatment of schizophrenia.^[1]^[2] It is a potent dopamine antagonist with high affinity to the D₂, D₃, and D₄ receptors,^[3] and with moderate affinity for the 5-HT₂ receptors.^[4]

References

^ Takahashi N, Terao T, Oga T, Okada M (1999). "Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia". Neuropsychobiology. 39 (2): 81–5. doi:10.1159/000026565. PMID 10072664. S2CID 6554048.
^ Miyamoto S (2010). "Mosapramine". In Stolerman IP (ed.). Encyclopedia of Psychopharmacology. Berlin, Heidelberg: Springer. p. 76. doi:10.1007/978-3-540-68706-1_1839. ISBN 978-3-540-68706-1. Retrieved 21 March 2022.
^ Futamura T, Ohashi Y, Yano K, Takahashi Y, Haga K, Fukuda T (May 1996). "[The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica. 107 (5): 247–53. doi:10.1254/fpj.107.247. PMID 8690306.
^ Sumiyoshi T, Suzuki K, Sakamoto H, Yamaguchi N, Mori H, Shiba K, Yokogawa K (February 1995). "Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy". Neuropsychopharmacology. 12 (1): 57–64. doi:10.1016/0893-133X(94)00064-7. PMID 7766287.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.